Cervical Intraepithelial Neoplasia News and Research

RSS

MedUni Vienna researchers develop new treatment for pre-stages of cervical cancer

Researchers at the Comprehensive Cancer Center of MedUni Vienna and Vienna General Hospital have developed a new treatment for the pre-stages of cervical cancer, caused by human papilloma virus (HPV) infection.

30 Mar 2016

CMFT adopts ZedScan system to improve cervical cancer care

DP Medical Systems Ltd has secured a deal with Central Manchester University Hospitals NHS Foundation Trust (CMFT) to adopt ZedScan™ as part of its cervical cancer care pathway.

From Zilico 21 Dec 2015

NeoGenomics introduces new NeoSITE Cervical FISH assay

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services, announced today an expansion of its comprehensive FISH (Fluorescence In Situ Hybridization) testing menu to include a new NeoSITE Cervical assay to provide additional diagnostic information on abnormal Pap smears.

23 Sep 2015

Janssen-sponsored Phase 2b trial shows guselkumab effective in treating moderate to severe plaque psoriasis

Results published today in The New England Journal of Medicine from a Janssen Research & Development, LLC (Janssen)-sponsored Phase 2b trial showed up to 86 percent of patients with moderate to severe plaque psoriasis receiving guselkumab (CNTO 1959) achieved a Physician's Global Assessment (PGA) score of cleared psoriasis or minimal psoriasis at week 16, the study's primary endpoint.

9 Jul 2015

PDS Biotechnology announces positive results from PDS0101 Phase I trial in pre-cervical cancer patients

PDS Biotechnology Corp. announces preliminary data showing that PDS0101, a cancer immunotherapy treatment targeting HPV-16, has generated strong T-cell responses in pre-cervical cancer patients.

28 May 2015

Merck announces availability of GARDASIL 9 HPV vaccine in Canada

Merck, known as MSD outside the United States and Canada, announced today that GARDASIL 9 (Human Papillomavirus 9-valent Vaccine, Recombinant), Merck's 9-valent human papillomavirus (HPV) vaccine, is now available in Canada.

1 Apr 2015

NICE publishes Medtech Innovation Briefing on ZedScan

The NICE MIB has been developed on ZedScan as an adjunct to colposcopy in women with suspected cervical intra-epithelial neoplasia.

From Zilico 23 Feb 2015

Study shows sustained immunogenicity, efficacy and safety of GlaxoSmithKline's HPV vaccine

A long-term follow-up study (HPV-023; NCT00518336) shows the sustained efficacy, immunogenicity and safety of GlaxoSmithKline's human papilloma virus (HPV) vaccine Cervarix.

1 Aug 2014

Researchers demonstrate novel approach in cervical cancer prevention

A study published online in the International Journal of Cancer earlier this month describes a novel approach to preventing cervical cancer based on findings showing successful reduction in the risk of cervical cancer after removal of a discrete population of cells in the cervix.

26 Jul 2014

Testing for HPV allows for longer time between screening tests

A new study from Karolinska Institutet in Sweden finds that testing for human papilloma virus (HPV) allows for longer time between screening tests when compared to cytology-based testing. The study is published in the scientific journal British Medical Journal (BMJ).

21 Jan 2014

Call for long follow-up after CIN3 treatment

Researchers from Sweden say that women who have been treated for cervical precancer should receive lifelong follow-up, after finding that their risk for dying from vaginal or cervical cancer markedly increases after the age of 60 years.

15 Jan 2014

New suppository developed for treatment of cervical pre-cancer

Infection with the human papillomavirus (HPV) can lead to cervical cancer via a preliminary stage - that of cervical intraepithelial neoplasia (CIN). In Europe 205,000 women every year are affected by this condition, most of them are aged between 25 and 30 years. Since in many cases slight manifestations of the disease (CIN 1) heal spontaneously, mostly no treatment is given but self-healing monitored by means of rigorous and continuous check-ups.

29 May 2013

Study evaluates effectiveness of 3 commonly used screening methods among South African women

The best approach to detecting cervical cancer in HIV-positive women living in research limited countries such as those in Sub-Saharan Africa combines commonly used testing methods tailored to local levels of development and medical infrastructure, according to a study by researchers from and the University of Witwatersrand in South Africa and the University of North Carolina.

16 Jan 2013

HPV testing and cervical screening: an interview with Dr Rosa Legood

Human papillomavirus is a virus that is transmitted through sexual contact. In most cases the virus is transient and causes no harm, however in some cases it can go on to cause pre-cancer lesions and cervical cancer.

7 Nov 2012

Cervical cancer risk remains high after CIN treatment

Women who undergo treatment for screening-detected cervical intraepithelial neoplasia are more than four times more likely to develop cervical cancer than women with normal smear tests, research suggests.

5 Nov 2012

HPV test of cure cheaper and more effective than cytology testing for women following pre-cervical cancer treatment

Testing women to see if they are cured of HPV (the virus that can cause genital warts and cervical cancer) following treatment for abnormal cells on the surface of the cervix is more effective and cheaper than cytology testing (cervical screening) alone, suggests a study published on bmj.com.

2 Nov 2012

Therapeutic HPV16 and HPV18 vaccine ‘may eliminate infection’

A candidate vaccine against human papillomavirus serotypes 16 and 18 appears to induce robust immune responses to antigens, potentially leading to the elimination of virus-infected cells and regression of dysplasia, say US investigators.

15 Oct 2012

Bivalent HPV vaccine has cross-protective effect, but could wane over time

The bivalent vaccine for human papillomavirus types 16 and 18 appears to be more efficacious against outcomes associated with nonvaccine types 31, 33, and 45 than its quadrivalent counterpart, show results of a systematic review and meta-analysis.

5 Oct 2012

HPV co-testing prospect for HIV-infected women

The risk for cervical precancer and cancer is similar in HIV-infected and HIV-uninfected women with normal cervical cytology and no evidence of oncogenic human papillomavirus infection, research shows.

30 Jul 2012

Study: HIV-infected women less likely to develop cervical cancer

HIV-infected and uninfected women with normal cervical cytology (Pap test) and a negative test result for oncogenic (tumor inducing) human papillomavirus DNA at study enrollment had a similar risk of cervical precancer and cancer after 5 years of follow-up, according to a study in the July 25 issue of JAMA, a theme issue on HIV/AIDS.

23 Jul 2012